

RÉSUMÉ DIGEST

ACT 469 (SB 169)

2026 Regular Session

Talbot

Existing law requires insurance coverage for biomarker testing when clinical utility is demonstrated.

New law retains existing law but limits coverage to the biomarker test itself. New law further prohibits conditioning coverage on laboratory classifications or credentialing standards unrelated to the performance of the covered test.

New law relative to coverage for biomarker testing of existing conditions prevails in the event of an inconsistency between new law and existing law relative to coverage for genetic testing to screen for cancer.

Effective May 29, 2026.

(Amends R.S. 22:1028.5(D); adds R.S. 22:1028.5(F))